Get the Stockscreener App
8.3033
1.33%
-0.1067
Amneal Pharmaceuticals Inc stock is traded at $8.3033, with a volume of 364.78K.
It is down -1.33% in the last 24 hours and down -4.07% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$8.41
Open:
$8.35
24h Volume:
364.78K
Relative Volume:
0.32
Market Cap:
$2.59B
Revenue:
$2.50B
Net Income/Loss:
$-168.69M
P/E Ratio:
-415.17
EPS:
-0.02
Net Cash Flow:
$124.24M
1W Performance:
-2.95%
1M Performance:
-4.07%
6M Performance:
+22.75%
1Y Performance:
+93.43%
1-Day Range:
$8.28
$8.415
1-Week Range:
$8.28
$8.66
52-Week Range:
$3.96
$8.95
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Earnings Preview: Amneal Pharmaceuticals (AMRX) Q3 Earnings Expected to Decline - Yahoo Finance
Amneal Pharmaceuticals (AMRX) Scheduled to Post Earnings on Friday - MarketBeat
Amneal Pharmaceuticals (NASDAQ:AMRX) grows 3.0% this week, taking five-year gains to 211% - Yahoo Finance
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Update - MarketBeat
Top Companies in the Phenazopyridine Market Set for Success - openPR
Assenagon Asset Management S.A. Purchases 642,065 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Amneal wins FDA approval for nerve agent pretreatment - Investing.com
Amneal wins FDA approval for nerve agent pretreatment By Investing.com - Investing.com Australia
Amneal Pharmaceuticals Gets FDA Approval for Pyridostigmine Bromide - MarketWatch
Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets - Business Wire
Amneal Pharmaceuticals (NASDAQ:AMRX) Sets New 12-Month HighWhat's Next? - MarketBeat
SG Americas Securities LLC Invests $531,000 in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Cardiac Sarcoidosis Drugs Global Market Report |Hikma Pharmaceuticals PLC, Mylan N.V, Amneal Pharmaceuticals LLC, Mallin – IndiaPolitics.com - IndiaPolitics.com
Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Azathioprine Tablets Industry to Witness an Outstanding Growth by 2030 |Mylan, Zydus Pharmaceuticals, Amneal Pharmaceuti – IndiaPolitics.com - IndiaPolitics.com
Glycopyrrolate Injection Market Growth Report |Accord Healthcare, Advanz Pharma, American Regent, Amneal Pharmaceuticals – IndiaPolitics.com - IndiaPolitics.com
Amneal to Build Two Manufacturing Facilities in Ahmedabad, Gujarat - Chemical Industry Digest
Weight loss drugs to be produced in two new plants in India - Investment Monitor
Sei Investments Co. Grows Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal to Report Third Quarter 2024 Results on November 8, 2024 - BioSpace
AQR Capital Management LLC Sells 321,305 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Pharmaceuticals : to Report Fourth Quarter and Full Year 2019 Results on February 26, 2020 - Marketscreener.com
American Century Companies Inc. Lowers Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by Hsbc Holdings PLC - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Position Lifted by Dimensional Fund Advisors LP - MarketBeat
Latham & Watkins Advises Metsera in Strategic Collaboration With Amneal - ILW.com
Amneal gets stock price target boost on Metsera collaboration By Investing.com - Investing.com Canada
Amneal and Metsera collaborate to supply obesity and metabolic disease medicines - MSN
Amneal Pharmaceuticals (NASDAQ:AMRX) Price Target Raised to $12.00 at Truist Financial - MarketBeat
Algert Global LLC Acquires 46,537 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Nantahala Capital Management LLC Purchases 50,000 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Truist maintains Buy on Amneal on new partnership By Investing.com - Investing.com Canada
Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price Up 3.6% - MarketBeat
Amneal and Metsera Partner to Target Obesity Market - TipRanks
Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases - BioSpace
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Acquired by Renaissance Technologies LLC - MarketBeat
Wall Street SWOT: Amneal Pharmaceuticals stock rides wave of growth and innovation - Investing.com
Pharmaceutical company sues Colorado over epinephrine price-cap law - MSN
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stake Lifted by BlackBarn Capital Partners LP - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Position Lifted by BlackBarn Capital Partners LP - Defense World
Investors in Amneal Pharmaceuticals (NASDAQ:AMRX) have seen splendid returns of 194% over the past five years - Simply Wall St
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by Victory Capital Management Inc. - MarketBeat
Victory Capital Management Inc. Reduces Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Amneal launches Parkinson's drug Crexont in US pharmacies - Investing.com
Amneal Latest Generic EpiPen Maker To Fight Colo. Law - Law360
Amneal launches Parkinson's drug Crexont in US pharmacies By Investing.com - Investing.com Canada
Amneal asks court to block Colorado's free allergy pen program - Reuters
Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease - BioSpace
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.16%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):